News

Integrative Corporate and Drug Development Engine

Company Launch

BLEEDnFIRE Therapeutics launches with non-dilutive funding to advance first-in-class pan-indication therapy for rare bleeding disorders

05/27/26

Read more

Nexus Company News

Massalia Therapeutics Wins the i-Lab 2025 Competition to Advance its Sole-in-Class SANF-Targeting Platform for Fibrosis, Neovascularization & Treatment-resistant Cancers

10/22/25

Read more

Nexus Company News

Roca Therapeutics Secures First-ever EMA Recognition of Radiation Maculopathy as Distinct Indication – and Orphan Drug Designation

08/26/25

Read more

Announcement

Landmark BioVentures (LBV) today announced key updates to its Executive team and Board of Directors as the company transitions into its next phase of strategic growth and development

06/25/25

Read more

Company Launch

Massalia Therapeutics launches to advance novel therapies for patients with complex conditions intersecting oncology and fibrosis

05/19/25

Read more

Strategic Alliance

Landmark BioVentures and G.CLIPS Biotech forge strategic alliance to address critical gaps in drug target engagement

04/23/25

Read more

Strategic Alliance

Landmark BioVentures strengthens immunology and oncology non-clinical capabilities through strategic alliance with Axis Bio

12/12/24

Read more

Company Launch

Duhn Therapeutics, launched by Landmark BioVentures, signs global license agreement with OM Pharma to further advance clinical-stage, lipid-based cancer immunotherapy

10/23/24

Read more

Company Launch

SPIMA Therapeutics Launches to Transform Peptide-Based Immunotherapies and Announces Global Licensing Agreement with SATT AxLR

09/30/24

Read more

Contact Us